GU Cancers 2024 | CABATEN/GETNE-T1914: cabozantinib plus atezolizumab in adrenocortical carcinoma

Enrique Grande, MD, MD Anderson Cancer Center Madrid, Madrid, Spain, discusses results from the Phase II CABATEN trial (NCT04400474) of cabozantinib and atezolizumab in patients with advanced and refractory adrenocortical carcinoma (ACC), who had progressed on prior chemotherapy and/or mitotane. Promising activity was reported in patients receiving the investigational therapy and safety was consistent with previous studies. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.